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The Diels-Alder Approach towards Cannabinoid Derivatives
and Formal Synthesis of Tetrahydrocannabinol (THC)
Thomas Hurrle,[a, b] Franziska Gläser,[a] Manuel C. Bröhmer,[a] Martin Nieger,[c] and
Stefan Bräse*[a, b]
Based on the Diels-Alder reaction of vinylchromenes with
electron-poor dienophiles, we developed a strategy for the
synthesis of tetrahydrocannabinol derivatives. Substituted vinyl
chromenes could be converted with several dienophiles to
successfully isolate several complex molecules. These molecules
already contain the cannabinoid-like base structure and further
processing of one such derivative led to a precursor of Δ9-
tetrahydrocannabinol. The most challenging step towards this
precursor was an epoxidation step that was ultimately achieved
via dimethyl dioxirane.
1. Introduction
Since their discovery more than 50 years ago,[1] cannabinoids,[2]
a group of around 60 secondary metabolites found in Cannabis
sativa, have received plenty of attention due to their immense
pharmacological capabilities. Their mode of action is based on
their effect on the endocannabinoid system, i. e. the cannabi-
noid-receptors, and new details are still uncovered.[3]
The most prominent compound, Δ9-tetrahydrocannabinol
(1, THC, Figure 1),[2] is responsible for the psychoactive effects of
C. sativa and has antiemetic and appetizing properties so that it
can be used for the treatment of e. g. anorexia in acquired
immune deficiency syndrome (AIDS)-patients[4] and nausea as a
side effect of chemotherapy.[5] Furthermore, it has proven to
have analgesic effects and can be used in pain management in
multiple sclerosis and neuropathic pain[6] or for the treatment of
the tics in Tourette’s syndrome.[7]
More than 20 total syntheses[8] for ΤHC and its derivatives
have been reported. However, it can be cost-effectively
produced by the extraction of several Cannabis strains or semi
synthetically by the extraction of Cannabidiol (2, CBD, Figure 1)
and a subsequent ring-closing procedure.[9] In this context,
synthetic efforts are not focused on THC but rather on analog
compounds that show stronger and/or more selective effects.
Research on cannabinoids is going strong and a journal
dedicated solely to give a platform to discuss all aspects of
cannabinoids has been created.[10] Furthermore, the search for
compounds to selectively address certain targets within the
endocannabinoid system is ongoing.
The design of novel compounds is often based on the
structure of THC (1); referred to as classical cannabinoids.[11]
However, non-related structures have been developed that can
influence the endocannabinoid system just as effectively. A
prominent example of non-classical cannabinoids is Rimona-
bant (3, Figure 1). It shows inverse agonistic effects on the CB-
receptors and had been developed as an appetite suppressant
to combat chronic obesity.[12] Unfortunately, rimonabant
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Figure 1. The phytocannabinoids THC (1) and CBD (2), non-classical
cannabinoid Rimonabant (3), and the classical cannabinoids Nabilone (4),
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showed severe psychiatric side effects and was consequently
suspended.[13]
Of the cannabinoids based on the THC structure, one of the
most functional is the synthetic compound Nabilone (4, Fig-
ure 1). Traded by the name of Cesamet® it shows similar activity
to THC and is used just like THC for the treatment of nausea as
a side effect of chemotherapy and against anorexia in AIDS
patients. Additionally, it has been shown, that it can be
beneficial for the relief of pain and functional movement in
fibromyalgia patients.[14] Not only has Nabilone (4) a better
bioavailability, moreover, the ratio of analgesic to psychoactive
effect is shifted towards the analgesic aspect when compared
to THC (1). The same clinical trial suggested that nabilone (4)
can enhance the positive mood while cognitive impairment is
on a low level.[15]
Still considered to be the most potent cannabinoid known
is HU-211 (5, Figure 1), a synthetic cannabinoid created by the
group of Mechoulam.[16] It is the reduced form of HU-210 (6,
Figure 1) which already exhibits a longer-lasting activity that is
100 to 800 fold higher when compared to THC (1). HU-210
promotes neurogenesis and thereby exhibits anxiolytic and
antidepressant effects.[17]
Strategies to synthesize classical cannabinoids cover a broad
range of approaches.[8] Minami and Coworkers have shown that
vinyl chromenes 7 (Scheme 1A) can undergo Diels-Alder
reactions.[18] However, they had to employ high reaction
temperatures and found that the resulting double bond
isomerized. In our last publication on the topic we reported
that the Diels-Alder reaction could be successfully implemented
with maleic anhydride for derivatives 10 that did not bear the
hydroxy group (Scheme 1B).[19] Subsequently, the Diels-Alder
products were successfully transformed into THC derivatives.
In this publication, we report the successful transfer of the
strategy to substrates, which fulfill the requirements of the THC
framework, a 7-alkyl substitution, and a 5-hydroxy group. The
substituted vinyl chromenes 13, methoxy modified versions of
7, serve as synthetic hubs toward further functionalization.
Access to the starting substrates 16a/16b is feasible by existing
protocols from phenol precursors 14a/14b. This suggests that a
large variety of analogs should be accessible by employing the
respective phenol derivatives.[19] With the right substitution
pattern, we could successfully synthesize a compound that has
been reported as an intermediate in a THC total synthesis,
thereby our protocol constitutes a formal synthesis.
2. Results and Discussion
Our modular strategy is centered around vinyl chromenes 13
which can undergo Diels-Alder reactions with a variety of
dienophiles (Scheme 2).[19] These Diels-Alder products 12 can be
further derivatized, which gives the potential to synthesize a
large library of cannabinoid compounds. The vinyl chromenes
13 are accessible through several steps from commercially
available resorcinol derivatives 14.
At first, the dimethylchromenes 16a and 16b were
synthesized (Scheme 3). One feasible pathway is a two-step
protocol in which a Friedel-Crafts acylation towards acylben-
zenes 15a and 15b is followed by an aldol reaction that has
been employed by Ko et al. for other derivatives.[20] The two-
step protocol gave sufficient material of the methyl-substituted
derivative 16a, while the pentyl substituted derivative 16b was
synthesized in a single step by a protocol according to Press
et al.[21] Here, olivetol (14b) reacts directly with 3,3-dimeth-
ylacryloyl chloride, resulting in dimethylchromene 16b.
Figure 2 shows the confirmation of the structures via X-ray
crystallography for 15a, 15b, and 16a.
The dimethylchromenes 16a and 16b, were then trans-
ferred to vinyl chromenes 13a and 13b in five synthetic steps
(Scheme 4). First, the phenolic hydroxyl groups of 16 are
protected as methoxy groups with methyl iodide in good to
excellent yields. For larger quantities, dimethyl sulfate in
acetone led to similar good results. The hydroxymethylation of
methoxy ethers 17 is achieved via lithiation at C-3 and the
Scheme 1. A): Diels-Alder-concept by Minami et al.: a) 10 equiv. acrylic acid
methyl ester, 1 equiv. DBU, DMF, 100 °C.[18] B): Diels-Alder-concept by Gläser
et al. b) maleic anhydride, CH3CN, r.t., 12 h.[19].
Scheme 2. Vinyl chromenes 13 as synthetic hub towards cannabinoids.[19]
Scheme 3. Synthesis of dimethylchromenes 16a and 16b via different
protocols. a) FeCl3, 3,3-Dimethylacryloyl chloride, chloroform, 12 h, r.t., 3 h,
40 °C, 16b 52%; b) AlCl3, C6H5Cl, AcCl, 30 min, 40 °C, then 45 min, 75 °C, 15a
77%, 15b 79%; c) acetone, pyrrolidine, toluene, 110 °C, 14 h, Dean-Stark
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addition of N-(hydroxymethyl)phthalimide as an electrophile. A
side product formed in this reaction when it was allowed to
warm up before quenching and is described in the supporting
information. Reduction to diols 19 and subsequent oxidation
that also triggers an elimination, leads to α, β-unsaturated
aldehydes 20. A Wittig reaction then transforms the aldehydes
to the vinyl chromenes 13a and 13b. The structures of 17a and
18a could be confirmed by X-ray crystallography and are
shown in Figure 3.
While the vinyl chromenes 13 have been successfully stored
at   20 °C and under argon atmosphere for several days, it is
recommended to transform them into the Diels-Alder product
as soon as possible. At room temperature, it was observed that
the vinyl chromene 13b shows signs of degradation, putatively
due to polymerization, oxidation, or dimerization. An attempt
to isolate and characterize the resulting compounds has not
been successful. Diels-Alder reactions were performed with the
substrate 13a (Scheme 5). The reaction with methyl maleic
anhydride led to a mixture of the regioisomers 21 and 22. With
a 34% yield, regioisomer 21 was the main product, whereas
only traces of the second regioisomer were found.
Conversion with maleic anhydride led under slightly differ-
ent conditions to anhydride 23 in 73% yield.
The relative configuration of the Diels-Alder products 21,
22, and 23 were confirmed via X-ray crystallography and are
shown in Figure 4.
Especially interesting are the products of vinyl chromene
13b, since they bear the pharmacophoric pentyl side chain
analog to THC. The Diels-Alder reactions performed with this
compound are compiled in Scheme 6. The reaction with maleic
anhydride showed the best result and gave chromene 24 in a
quantitative yield. The other employed dienophiles ethyl (E)-4-
oxobut-2-enoate, methyl maleic anhydride and bromo maleic
anhydride led to smaller yields. However, in contrast to reaction
a) two regioisomers can be obtained in those reactions, which
makes a column chromatographic step necessary. For reactions
b) and c) both regioisomers could be separated while for d)
only one regioisomer has been isolated. We assume that the
significantly lower overall isolated yields can be explained by
loss in the chromatographic step due to the polar character of
the products and the possibility of hydrolytic degradation on
the stationary phase. Additionally, the longer required reaction
times that were needed for complete conversion of reactions b)
to d) could allow the rather delicate diene to degrade.
The Diels-Alder Product 24 was then transformed in several
additional steps to chromene 35 (Scheme 7). Several conditions
for the hydration of the double bond were tested and complete
Figure 2. Molecular crystal structures of 15a (one of the two crystallographic
independent molecules), 16a, and 15b (displacements are drawn at 50%
probability levels).
Scheme 4. Synthesis of vinyl chromenes 13a and 13b: a) MeI, K2CO3, DMF,
reflux, 12 h, 82% 17a, 95% 17b; b) Me2S2O4, Acetone, reflux, 4 h, 97% 17b;
c) LiTMP, N-(hydroxymethyl)phthamimide, THF,   78 °C, 2 h, 82% 18a, 82%
18b; d) LiAlH4, THF, 0 °C bis r. t., 2 h, 77% 19a, >98% 19b; e) Oxalyl
chloride, DMSO, Et3N, CH2Cl2,   55 °C, 3 h, 80% 20a, 89% 20b; f) MePPh3Br,
t-BuOK, THF,   78 °C to r. t., 30 min, 81% 13a, 95% 13b.
Figure 3. Molecular structures of 17a and 18a (displacements are drawn at
50% probability levels).
Scheme 5. Diels-Alder modification of 13a: a) methyl maleic anhydride,
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conversion to 30 was observed with 25 mol% Pd/C catalyst
loading in a pressurized reactor with a 20 bar hydrogen
atmosphere. Subsequently, the anhydride was hydrolyzed
followed by an oxidative decarboxylation to alkene 32. The
epoxidation of alkene 32 proved to be a challenging endeavor
as harsh conditions (e.g. m-CPBA, H2O2) resulted in over-
oxidation and too mild conditions (e.g.H2O2/urea) showed no
conversions. The tested reaction conditions are summarized in
Table 1. Ultimately it was found that the epoxidation proceeded
with the highest yield by employing dimethyl dioxirane
(DMDO). The DMDO was freshly prepared according to Taber
et al..[22] The absolute cis configuration of epoxide 33 was
confirmed via the NOESY technique and a ring-opening
reaction performed, which resulted in alcohol 34. This alcohol
was then oxidized to literature known α,β-unsaturated ketone
35 which can be described as a precursor for THC since all
Figure 4. Molecular structures of 21, 22, and 23 (displacements are drawn at 50% probability levels).
Scheme 6. Diels-Alder reactions with diene 13b: a) maleic anhydride, ACN,
0 °C to r.t., 16 h, 24, quant.; b) ethyl (E)-4-oxobut-2-enoate, DCM, 0 °C to r.t.,
36 h, 25 14%, 26 7%. c) methyl maleic anhydride, ACN, 0 °C to r.t., 60 h, 27
33%, 28 10%; d) bromo maleic anhydride, ACN, 0 °C to r.t., 36 h, 29 17%,
second regioisomer was not isolated.
Scheme 7. Modification of Diels-Alder product 24. a) 25 mol% Pd/C, 20 bar
H2, EtOAc, 16 h, 99%; b) NaHCO3  Lsg., 80 °C, 3–12 h, 0 °C, HCl, 98%; c)
Pb(OAc)4, pyridine, 55 °C, 2 h, 43%; d) DMDO, Acetone, 2 h 0 °C, 30%; e)
MeLi, THF,   78 °C bis r. t. 12 h; f) Dess-Martin periodinane, CH2Cl2, 1 h, r. t.,
49%.
Table 1. Summary of tested epoxidation reactions with alkene 32: A: m-
CPBA (70%), DCM, 0 °C to r.t., 12 h; B: m-CPBA (99%), DCM, 0 °C to r.t., 12 h;
C: TFAA, CO(NH2)2 ·H2O2, DCM, 0 °C, 2 h; D: 2.00 equiv. H2O2, NaOH, iPrOH,
0 °C, 2 h, r.t., 12 h; E: 1.00 equiv. DMDO, acetone, 0 °C, 2 h, r.t., 12 h. F:
1.50 equiv. DMDO, acetone, 0 °C, 2 h, volatiles removed in high vacuum
with a cooling trap.
Entry Conditions Oxidant Isolated yield 33 [%]
1 A m-CPBA 70% 2
2 B m-CPBA 99% 9
3 C CO(NH2)2 ·H2O2 –
[a]
4 D H2O2 –
[b]
5 E DMDO 23
6 F DMDO 28
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necessary conversions have been reported.[23] The relative
configuration of the Diels-Alder products 24 and the dicarbox-
ylic acid 31 was confirmed via X-ray crystallography and is
shown in Figure 5.
3. Conclusions
Vinyl chromenes 13 can be synthesized via a multi-step reaction
protocol from resorcinol derivatives. The chromenes can then
undergo Diels-Alder reactions with electron-poor dienophiles to
give classical cannabinoid-like tricycles. Especially the reaction
with maleic anhydride to anhydride 24 is highly interesting and
gives high yields.
From anhydride 24, a reaction sequence was developed
that allowed the conversion to ketone 35, which constitutes the
formal synthesis of THC as further reaction protocols have been
published. The novel compounds synthesized in this work
constitute potential cannabinoid analogs and could be used in
structure-activity relationship studies for the development of
highly active ligands for the cannabinoid receptors.
Experimental Section
X-ray Crystal Structure Determination
The single-crystal X-ray diffraction studies were carried out on a
BrukerNonius KappaCCD diffractometer at 123(2) K using Mo  Ka
radiation (λ=0.71073 Å) (15a, 16a, 15b, 17a, 18a, 21, 22, 23) or
an Agilent SuperNova Dual diffractometer with Atlas detector at
123(2) K using Cu  Ka radiation (λ=1.54178 Å) (24, 31). Direct
Methods (SHELXS-97)[24] were used for structure solution and
refinement was carried out using SHELXL-97[24] or SHELXL-2013[25]
(full-matrix least-squares on F2). Hydrogen atoms were localized by
difference electron density determination and refined using a riding
model (H(O)) free. Semi-empirical absorption corrections were
applied for 24 and 31.
15a: colorless crystals, C9H10O3, Mr=166.17, crystal size 0.30×0.10×
0.05 mm, monoclinic, space group P21/c (No. 14), a=3.896(1) Å, b=
27.004(3) Å, c=14.957(2) Å, β=91.90(1)°, V=1572.7(5) Å3, Z=8,
1=1.404 Mg/m  3, μ(Mo  Kα)=0.105 mm
  1, F(000)=704, 2θmax=
50.0°, 10489 reflections, of which 2771 were independent (Rint=
0.082), 233 parameters, 4 restraints, R1=0.057 (for 1761 I >2σ(I)),
wR2=0.149 (all data), S=1.03, largest diff. peak/hole=0.223/
  0.340 eÅ  3.
15a is a redetermination of (2,6-dihydroxy-4-methylphenyl)
ethanone at 123 K [CCDC-732688, S. K.Seth, D.K. Hazra, M.
Mukherjee, T.Kar, Journal of Molecular Structure, 2009, 936, 277–282,
DOI: 10.1016/j.molstruc.2009.08.013].
15b: colorless crystals, C12H14O3, Mr=206.23, crystal size 0.50×
0.30×0.20 mm, orthorhombic, space group Pbca (No. 61), a=
6.452(1) Å, b=16.056(2) Å, c=19.953(2) Å, V=2067.0(5) Å3, Z=8,
1=1.325 Mg/m  3, μ(Mo  Kα)=0.095 mm
  1, F(000)=880, 2θmax=
55.0°, 14289 reflections, of which 2374 were independent (Rint=
0.024), 142 parameters, 1 restraint, R1=0.037 (for 2057 I >2σ(I)),
wR2=0.103 (all data), S=1.03, largest diff. peak/hole=0.310/
  0.181 eÅ  3.
16a: yellow crystals, C13H18O3, Mr=222.27, crystal size 0.24×0.12×
0.08 mm, monoclinic, space group P21/n (No. 14), a=8.156(1) Å, b=
12.127(1) Å, c=12.250(1) Å, β=91.82(1)°, V=1211.0(2) Å3, Z=4,
1=1.219 Mg/m  3, μ(Mo  Kα)=0.085 mm
  1, F(000)=480, 2θmax=
55.0°, 16004 reflections, of which 2766 were independent (Rint=
0.046), 152 parameters, 2 restraints, R1=0.047 (for 1949 I >2σ(I)),
wR2=0.116 (all data), S=1.03, largest diff. peak/hole=0.261/
  0.181 eÅ  3.
17a: colorless crystals, C13H16O3, Mr=220.26, crystal size 0.36×
0.30×0.03 mm, triclinic, space group P-1 (No. 2), a=5.600(1) Å, b=
8.754(1) Å, c=11.880(1) Å, α=74.74(1)°, β=86.02(1)°, γ=83.74(1)°,
V=558.00(13) Å3, Z=2, 1=1.311 Mg/m  3, μ(Mo  Kα)=0.092 mm
  1,
F(000)=236, 2θmax=55.0°, 8935 reflections, of which 2559 were
independent (Rint=0.053), 149 parameters, R1=0.054 (for 1936 I
>2σ(I)), wR2=0.142 (all data), S=1.04, largest diff. peak/hole=
0.321/  0.248 eÅ  3.
18a: colorless crystals, C14H18O4, Mr=250.28, crystal size 0.30×
0.20×0.15 mm, monoclinic, space group P21/n (No. 14), a=
6.0039(4) Å, b=21.0202(13) Å, c=10.3763(8) Å, β=106.281(4)°, V=
1257.01(15) Å3, Z=4, 1=1.323 Mg/m  3, μ(Mo  Kα)=0.096 mm
  1,
F(000)=536, 2θmax=50.0°, 6143 reflections, of which 2185 were
independent (Rint=0.046), 168 parameters, 1 restraint, R1=0.049
(for 1580 I >2σ(I)), wR2=0.123 (all data), S=1.04, largest diff. peak/
hole=0.225/  0.229 eÅ  3.
21: colorless crystals, C20H22O5, Mr=342.38, crystal size 0.30×0.12×
0.06 mm, monoclinic, space group P21/n (No. 14), a=9.726(1) Å, b=
11.069(1) Å, c=16.369(2) Å, β=99.90(1)°, V=1736.0(3) Å3, Z=4,
1=1.310 Mg/m  3, μ(Mo  Kα)=0.094 mm
  1, F(000)=728, 2θmax=
55.0°, 19159 reflections, of which 3975 were independent (Rint=
0.060), 228 parameters, R1=0.056 (for 2942 I >2σ(I)), wR2=0.149
(all data), S=1.02, largest diff. peak/hole=0.363/  0.330 eÅ  3.
22: colorless crystals, C20H22O5, Mr=342.38, crystal size 0.48×0.16×
0.08 mm, monoclinic, space group P21/c (No. 14), a=11.055(1) Å,
b=12.230(1) Å, c=12.692(1) Å, β=94.15(1)°, V=1711.5(2) Å3, Z=4,
1=1.329 Mg/m  3, μ(Mo  Kα)=0.095 mm
  1, F(000)=728, 2θmax=
55.0°, 16881 reflections, of which 3291 were independent (Rint=
0.035), 228 parameters, R1=0.046 (for 2965 I >2σ(I)), wR2=0.119
(all data), S=1.03, largest diff. peak/hole=0.288/  0.257 eÅ  3.
23: colorless crystals, C19H20O5, Mr=328.35, crystal size 0.28×0.08×
0.03 mm, triclinic, space group P-1 (No. 2), a=5.5653(5) Å, b=
10.3182(15) Å, c=14.6468(7) Å, α=107.767(7)°, β=94.964(6)°, γ=
96.607(9)°, V=789.02(14) Å3, Z=2, 1=1.382 Mg/m  3, μ(Mo  Kα)=
0.100 mm  1, F(000)=348, 2θmax=50.0°, 9012 reflections, of which
2763 were independent (Rint=0.108), 219 parameters, R1=0.107
(for 1539 I >2σ(I)), wR2=0.304 (all data), S=1.09, largest diff. peak/
hole=0.534/  0.457 eÅ  3.
24: colorless crystals, C23H28O5, Mr=384.45, crystal size 0.20×0.08×
0.02 mm, triclinic, space group P-1 (No. 2), a=11.5457(3) Å, b=
11.5996(6) Å, c=16.0800(7) Å, α=72.497(4)°, β=88.706(3)°, γ=
87.052(3)°, V=2051.04(15) Å3, Z=4, 1=1.245 Mg/m  3, μ(Cu  Kα)=
Figure 5. Molecular structures of 24 (one of the two crystallographic
independent molecules) and 31 (minor disordered parts omitted for clarity,
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0.703 mm  1, F(000)=824, 2θmax=147.0°, 13940 reflections, of which
7972 were independent (Rint=0.037), 497 parameters, 177 restraint,
R1=0.069 (for 6940 I >2σ(I)), wR2=0.205 (all data), S=1.04, largest
diff. peak/hole=0.757/  0.511 eÅ  3. In both crystallographic inde-
pendent molecules the pentyl-substituents are disordered and
disordered atoms were refined isotropically (see cif-file for details).
31: colorless crystals, C23H32O6, Mr=404.48, crystal size 0.30×0.20×
0.03 mm, monoclinic, space group P21/c (No. 14), a=14.109(3) Å,
b=15.579(2) Å, c=10.487(1) Å, β=106.60(2)°, V=2209.0(6) Å3, Z=
4, 1=1.216 Mg/m  3, μ(Cu  Kα)=0.708 mm
  1, F(000)=872, 2θmax=
148.4°, 6717 reflections, of which 4217 were independent (Rint=
0.062), 262 parameters, 79 restraints, R1=0.094 (for 2773 I >2σ(I)),
wR2=0.254 (all data), S=1.06, largest diff. peak/hole=0.493/
  0.362 eÅ  3. The pentyl-substituent is disordered and disordered
atoms were refined isotropically (see cif-file for details).
https://www.ccdc.cam.ac.uk/services/structures?id=doi:10.1002/
open.2020000343 Deposition Numbers 1853371 (15a), 1853373
(15b), 1853372 (16a), 1853374 (17a), 1853375 (18a), 1853378 (21),
1853377 (22), 1853376 (23), 1853379 (24), and 1853380 (31) contain
the supplementary crystallographic data for this paper. These data
are provided free of charge by the joint Cambridge Crystallographic
Data Centre and Fachinformationszentrum Karlsruhe Access Struc-
tures service www.ccdc.cam.ac.uk/structures/?.
Supporting Information (see footnote on the first page of this
article): Full experimental procedures and detailed spectroscopic
data for all compounds.
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